BioSpace News Archive

Avenge Bio, Inc. (“Avenge” or the “Company”), a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced that two abstracts were selected for presentation as posters at the 25th Annual American Society of Gene & Cell Therapy (ASGCT) Meeting.

In 2021, the FDA approved 122 New Drug Applications (NDAs) and Biologics License Applications (BLAs), including new molecular entities (NMEs), biologics approved as BLAs through the Center for Biologics Evaluation and Research (CBER), and new formulations of older drugs.

Athira Pharma, Inc. announced, based on the preliminary vote count provided by its proxy solicitor, that Athira’s shareholders have approved the election of all three of Athira’s highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – to the company’s board of directors.

The genetic engineering has enabled the identification of several genetic diseases as well as the novel genes which are associated with their development.

The advent of antibody therapeutics represents breakthrough therapy in the management of wide range of cancers including various subtypes of lymphoma.

Metabolon, Inc., the global leader in providing metabolomics solutions that advance drug development and precision medicine, has appointed Sean Iverson as Vice President of Global Marketing.

Blue Water Vaccines, Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing vaccines, announces a collaboration with the multidisciplinary Center for R&D in Immunobiologics (“CeRDI”), an initiative of Instituto Butantan (“Butantan”).

The Battelle National Biodefense Institute and Frederick County Public Schools yesterday announced the recipients of $50,000 in teacher challenge grants for science, technology, engineering and math education.

Toronto, Ontario--(Newsfile Corp. - May 19, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today the completion of the world’s first ketamine treatment study for behavioral addictions.

OKYO Pharma Limited announced the closing of its underwritten public offering of 625,000 American Depository Shares at a public offering price of $4.00 per share, for gross proceeds of $2.5 million, before deducting underwriting discounts and offering expenses.